Article | Published:

Nicotine normalizes cortico-striatal connectivity in non-smoking individuals with major depressive disorder

Neuropsychopharmacologyvolume 43pages24452451 (2018) | Download Citation

Subjects

Abstract

Nicotine dependence and major depressive disorder (MDD) are highly comorbid, yet causal links between these prevalent disorders are unclear. One possible mechanism is that nicotine ameliorates MDD-related neurobiological dysfunction in specific networks. For instance, cortico-striatal circuitry is enhanced by nicotine, and such paths are disrupted in individuals with MDD. Specifically, MDD has been associated with reduced connectivity between the nucleus accumbens (NAc) and rostral anterior cingulate cortex (rACC) but enhanced connectivity between the dorsal striatum (DS) and dorsolateral prefrontal cortex (DLPFC). Determining whether nicotine normalizes these circuits in non-smokers with MDD may elucidate mechanisms underlying links between disorders. This was tested by administering placebo and a 2-mg dose of nicotine to unmedicated non-smokers with and without MDD prior to collecting resting-state functional magnetic imaging data using a cross-over design. On placebo, individuals with MDD showed significantly reduced NAc–rACC and a trend for enhanced DS–DLPFC functional connectivity relative to healthy controls. In MDD, acute nicotine administration normalized both pathways to the level of healthy controls, while having no impact on healthy controls. Nicotine’s effects on NAc–rACC connectivity was influenced by anhedonia, consistent with the role of this network in reward and nicotine’s ability to enhance reward deficiencies in MDD. These results indicate that nicotine normalizes dysfunctional cortico-striatal communication in unmedicated non-smokers with MDD. Nicotine’s influence on these circuitries highlights a possible mechanism whereby individuals with MDD are more vulnerable to develop nicotine dependence. Findings suggest that nicotinic agents may have therapeutic effects on disrupted cortico-striatal connectivity.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Diwan A, Castine M, Pomerleau CS, Meador-Woodruff JH, Dalack GW. Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders. Schizophr Res. 1998;33:113–8.

  2. 2.

    Glassman AH, Helxer JE, Covey LS, Cottler LB, Stetner F, Tipp JE, et al. Smoking, smoking cessation, and major depression. JAMA. 1990;264:1546–9.

  3. 3.

    Fluharty M, Taylor AE, Grabski M, Munafò MR. The association of cigarette smoking with depression and anxiety: a systematic review. Nicotine Tob Res. 2017;19(1):3–13.

  4. 4.

    Picciotto MR, Lewis AS, van Schalkwyk GI, Mineur YS. Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states. Neuropharmacol. 2015;96(B):235–43.

  5. 5.

    Furman DJ, Hamilton JP, Gotlib IH. Frontostriatal functional connectivity in major depressive disorder. Biol Mood Anxiety Disord. 2011;1(1):11.

  6. 6.

    Kaiser RH, Andrews-Hanna JR, Wager TD, Pizzagalli DA. Large-scale network dysfunction in major depressive disorder: a meta-analysis of resting-state functional connectivity. JAMA Psychiatry. 2015;72(6):603–11.

  7. 7.

    Kaiser RH, Treadway MT, Wooten DW, Kumar P, Goer F, Murray L, et al. Frontostriatal and dopamine markers of individual differences in reinforcement learning: a multi-modal investigation. Cereb Cortex. 2017. https://doi.org/10.1093/cercor/bhx281

  8. 8.

    Admon R, Pizzagalli DA. Corticostriatal pathways contribute to the natural time course of positive mood. Nat Commun. 2015;6:10065.

  9. 9.

    Leventhal A, Ramsey S, Brown R, LaChance H, Kahler C. Dimensions of depressive symptoms and smoking cessation. Nicotine Tob Res. 2008;10(3):507–17.

  10. 10.

    Leventhal AM, Waters AJ, Kahler CW, Ray LA, Sussman S. Relations between anhedonia and smoking motivation. Nicotine Tob Res. 2009;11(9):1047–54.

  11. 11.

    Carton S, Le Houezec J, Lagrue G, Jouvent R. Early emotional disturbances during nicotine patch therapy in subjects with and without a history of depression. J Affect Disord. 2002;72:195.

  12. 12.

    Ferrari R, Le Novère N, Picciotto MR, Changeux JP, Zoli M. Acute and long-term changes in the mesolimbic dopamine pathway after systemic or local single nicotine injections. Eur J Neurosci. 2002;15(11):1810–8.

  13. 13.

    Kenny PJ, Markou A. Nicotine self-administration acutely activates brain reward systems and induces a long-lasting increase in reward sensitivity. Neuropsychopharmacology. 2006;31(6):1203–11.

  14. 14.

    Barr RS, Pizzagalli DA, Culhane MA, Goff DC, Evins AE. A single dose of nicotine enhances reward responsiveness in nonsmokers: implications for development of dependence. Biol Psychiatry. 2008;63(11):1061–5.

  15. 15.

    Janes AC, Pedrelli P, Whitton AE, Pechtel P, Douglas S, Martinson MA, et al. Reward responsiveness varies by smoking status in women with a history of major depressive disorder. Neuropsychopharmacology. 2015;40(8):1940–6.

  16. 16.

    Pergadia ML, Der-Avakian A, D’Souza MS, Madden PAF, Heath AC, Shiffman S, et al. Association between nicotine withdrawal and reward responsiveness in humans and rats. JAMA Psychiatry. 2014;71(11):1238–45.

  17. 17.

    Kerestes R, Harrison BJ, Dandash O, Stephanou K, Whittle S, Pujol J, et al. Specific functional connectivity alterations of the dorsal striatum in young people with depression. NeuroImage Clin. 2015;7(C):266–72.

  18. 18.

    Avissar M, Powell F, Ilieva I, Respino M, Gunning FM, Liston C, et al. Functional connectivity of the left DLPFC to striatum predicts treatment response of depression to TMS. Brain Stimul. 2017;10(5):919–25.

  19. 19.

    First MB, Spitzer RL, Gibbon M, Williams JB. Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edition. SCID-I/P. New York: Biometrics Research, New York State Psychiatric Institute, 2002.

  20. 20.

    Hamilton M. A rating scale for depression. J Neurol Neurosurg PS. 1960;23:56–62.

  21. 21.

    Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50–55.

  22. 22.

    Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiat. 1995;167(1):99–103.

  23. 23.

    Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988;54:1063–70.

  24. 24.

    Choi J, Dresler C, Norton M, Strahs K. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res. 2003;5(5):635–44.

  25. 25.

    Benowitz NL, Jacob P. Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther. 1984;35(4):499–504.

  26. 26.

    McCarthy JM, Zuo CS, Shepherd JM, Dias N, Lukas SE, Janes AC. Reduced interhemispheric executive control network coupling in men during early cocaine abstinence: a pilot study. Drug Alcohol Depend. 2017;181:1–4.

  27. 27.

    Choi EY, Yeo BT, Buckner RL. The organization of the human striatum estimated by intrinsic functional connectivity. J Neurophysiol. 2012;108(8):2242–63.

  28. 28.

    Sutherland MT, Ray KL, Riedel MC, Yanes JA, Stein EA, Laird AR. Neurobiological impact of nicotinic acetylcholine receptor agonists: an activation likelihood estimation meta-analysis of pharmacologic neuroimaging studies. Biol Psychiatry. 2015;78(10):711–20.

  29. 29.

    Petrides M. Lateral prefrontal cortex: architectonic and functional organization. Philos Trans R Soc Lond B Biol Sci. 2005;360(1456):781–95.

  30. 30.

    Curtis CE, D’Esposito M. Persistent activity in the prefrontal cortex during working memory. Trends Cogn Sci. 2003;7(9):415–23.

  31. 31.

    Yeo BT, Krienen FM, Sepulcre J, Sabuncu MR, Lashkari D, Hollinshead M, et al. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J Neurophysiol. 2011;106(3):1125–65.

  32. 32.

    Latora V, Marchiori M. Efficient behavior of small-world networks. Phys Rev Lett. 2001;87(19):440–4.

  33. 33.

    Bullmore E, Sporns O. Complex brain networks: graph theoretical analysis of structural and functional systems. Nat Rev Neurosci. 2009;10(3):186–98.

  34. 34.

    Haber S. Parallel and integrative processing through the Basal Ganglia reward circuit: lessons from addiction. J Neurosci. 2008;64(3):173–4.

  35. 35.

    Haber SN, Knutson B. The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology. 2009;35(1):4–26.

  36. 36.

    Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiat. 1999;156(5):675–82.

  37. 37.

    Adermark L, Morud J, Lotfi A. Temporal rewiring of striatal circuits initiated by nicotine. Neuropsychopharmacology. 2016;41:1–33.

  38. 38.

    Brazell MP, Mitchell SN, Joseph MH, Gray JA. Acute administration of nicotine increases the invivo extracellular levels of dopamine, 3,4-dihydrozyphenylacetic acid and ascorbic acid preferentially in the nucleus accumbens of the rat: comparison with caudate-putamen. Neuropharmacology. 1990;29:1177–85.

  39. 39.

    Hill, DF, Parent, KL, Atcherley, CW, Cowen, SL, Heien, ML. Differential release of dopamine in the nucleus accumbens evoked by low-versus high-frequency medial prefrontal cortex stimulation. Brain Stimul. 2017;11:426–34. https://doi.org/10.1016/j.brs.2017.11.010.

  40. 40.

    Strafella AP, Paus T, Barrett J, Dagher A. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. J Neurosci. 2001;21(15):RC157.

  41. 41.

    McClernon FJ, Hiott FB, Westman EC, Rose JE, Levin ED. Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial. Psychopharmacol. 2006;189(1):125–33.

  42. 42.

    Giessing C, Thiel CM, Alexander-Bloch AF, Patel AX, Bullmore ET. Human brain functional network changes associated with enhanced and impaired attentional task performance. J Neurosci. 2013;33(14):5903–14.

  43. 43.

    Rahman S. Targeting brain nicotinic acetylcholine receptors to treat major depression and co-morbid alcohol or nicotine addiction. CNS Neurol Disord Drug Targets. 2015;14(5):647–53.

Download references

Acknowledgements

This project was supported by the National Institute on Drug Abuse grants K10 DA029645 and K02 DA042987 (ACJ). DAP was partially supported by National Institute of Mental Health grant R37 MH068376. Over the past 3 years, DAP has received consulting fees from Akili Interactive Labs, BlackThorn Therapeutics, Boehringer Ingelheim, Pfizer and Posit Science, for activities unrelated to the current research.

Author information

Affiliations

  1. McLean Hospital, Belmont, MA, 02478, USA

    • Amy C. Janes
    • , Maya Zegel
    • , Kyoko Ohashi
    • , Jennifer Betts
    • , Elena Molokotos
    • , David Olson
    • , Lauren Moran
    •  & Diego A. Pizzagalli
  2. Harvard Medical School, Boston, MA, USA

    • Amy C. Janes
    • , Kyoko Ohashi
    • , David Olson
    • , Lauren Moran
    •  & Diego A. Pizzagalli

Authors

  1. Search for Amy C. Janes in:

  2. Search for Maya Zegel in:

  3. Search for Kyoko Ohashi in:

  4. Search for Jennifer Betts in:

  5. Search for Elena Molokotos in:

  6. Search for David Olson in:

  7. Search for Lauren Moran in:

  8. Search for Diego A. Pizzagalli in:

Competing interests

The authors declare no competing interests.

Corresponding author

Correspondence to Amy C. Janes.

Electronic supplementary material

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/s41386-018-0069-x